Logo image of BIOC

BIOCEPT INC (BIOC) Stock Fundamental Analysis

NASDAQ:BIOC - Nasdaq - US09072V6002 - Common Stock - Currency: USD

0.4349  -0.07 (-13.05%)

After market: 0.39 -0.04 (-10.32%)

Fundamental Rating

1

BIOC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. BIOC has a bad profitability rating. Also its financial health evaluation is rather negative. BIOC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIOC has reported negative net income.
BIOC had a negative operating cash flow in the past year.
In the past 5 years BIOC always reported negative net income.
In the past 5 years BIOC reported 4 times negative operating cash flow.
BIOC Yearly Net Income VS EBIT VS OCF VS FCFBIOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -239.73%, BIOC is doing worse than 94.21% of the companies in the same industry.
With a Return On Equity value of -18271.38%, BIOC is not doing good in the industry: 87.58% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -239.73%
ROE -18271.38%
ROIC N/A
ROA(3y)-48.71%
ROA(5y)-115.34%
ROE(3y)-148.29%
ROE(5y)-299.94%
ROIC(3y)N/A
ROIC(5y)N/A
BIOC Yearly ROA, ROE, ROICBIOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

BIOC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOC Yearly Profit, Operating, Gross MarginsBIOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

BIOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIOC has been increased compared to 1 year ago.
BIOC has a worse debt/assets ratio than last year.
BIOC Yearly Shares OutstandingBIOC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
BIOC Yearly Total Debt VS Total AssetsBIOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -26.33, we must say that BIOC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BIOC (-26.33) is worse than 92.05% of its industry peers.
BIOC has a Debt/Equity ratio of 4.70. This is a high value indicating a heavy dependency on external financing.
BIOC's Debt to Equity ratio of 4.70 is on the low side compared to the rest of the industry. BIOC is outperformed by 86.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.7
Debt/FCF N/A
Altman-Z -26.33
ROIC/WACCN/A
WACC12.08%
BIOC Yearly LT Debt VS Equity VS FCFBIOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

BIOC has a Current Ratio of 1.81. This is a normal value and indicates that BIOC is financially healthy and should not expect problems in meeting its short term obligations.
BIOC has a worse Current ratio (1.81) than 82.78% of its industry peers.
BIOC has a Quick Ratio of 1.70. This is a normal value and indicates that BIOC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.70, BIOC is not doing good in the industry: 81.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.7
BIOC Yearly Current Assets VS Current LiabilitesBIOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BIOC have decreased strongly by -42970.00% in the last year.
The Revenue for BIOC has decreased by -54.64% in the past year. This is quite bad
The Revenue has been growing by 38.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-42970%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.42%
Revenue 1Y (TTM)-54.64%
Revenue growth 3Y67.22%
Revenue growth 5Y38.52%
Sales Q2Q%-94.45%

3.2 Future

BIOC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.57% yearly.
Based on estimates for the next years, BIOC will show a very negative growth in Revenue. The Revenue will decrease by -18.32% on average per year.
EPS Next Y86.86%
EPS Next 2Y40.26%
EPS Next 3Y25.57%
EPS Next 5YN/A
Revenue Next Year-93.72%
Revenue Next 2Y-59.48%
Revenue Next 3Y-18.32%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BIOC Yearly Revenue VS EstimatesBIOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BIOC Yearly EPS VS EstimatesBIOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOC Price Earnings VS Forward Price EarningsBIOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOC Per share dataBIOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30 -40

4.3 Compensation for Growth

BIOC's earnings are expected to grow with 25.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.26%
EPS Next 3Y25.57%

More info and screens

0

5. Dividend

5.1 Amount

BIOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCEPT INC

NASDAQ:BIOC (10/24/2023, 8:22:08 PM)

After market: 0.39 -0.04 (-10.32%)

0.4349

-0.07 (-13.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-20 2023-11-20/amc
Inst Owners0.43%
Inst Owner Change0%
Ins Owners153.09%
Ins Owner Change0%
Market Cap1.05M
Analysts43.33
Price Target4.08 (838.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)83.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-63.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 3.61
P/tB 3.61
EV/EBITDA N/A
EPS(TTM)-43.07
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-7.59
FCFYN/A
OCF(TTM)-7.31
OCFYN/A
SpS11.68
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -239.73%
ROE -18271.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.71%
ROA(5y)-115.34%
ROE(3y)-148.29%
ROE(5y)-299.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.27
Health
Industry RankSector Rank
Debt/Equity 4.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.18%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.7
Altman-Z -26.33
F-Score2
WACC12.08%
ROIC/WACCN/A
Cap/Depr(3y)77.11%
Cap/Depr(5y)65.93%
Cap/Sales(3y)2.95%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42970%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.42%
EPS Next Y86.86%
EPS Next 2Y40.26%
EPS Next 3Y25.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3Y67.22%
Revenue growth 5Y38.52%
Sales Q2Q%-94.45%
Revenue Next Year-93.72%
Revenue Next 2Y-59.48%
Revenue Next 3Y-18.32%
Revenue Next 5YN/A
EBIT growth 1Y-354.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-174%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-251.34%
OCF growth 3YN/A
OCF growth 5YN/A